CLINICAL TRIALS PROFILE FOR PROTOPIC
✉ Email this page to a colleague
All Clinical Trials for PROTOPIC
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00106496 ↗ | A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis | Completed | Astellas Pharma Inc | Phase 4 | 2004-10-01 | The purpose of the study is to determine the impact of topical corticosteroids on the safety and effectiveness of Protopic Ointment in the short-term treatment of moderate to severe Atopic Dermatitis and to compare the safety and effectiveness of Protopic Ointment to placebo in the long-term management of Atopic Dermatitis |
| NCT00236171 ↗ | Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test | Completed | Technische Universität Dresden | N/A | 2004-09-01 | The purpose of this study is to evaluate the efficacy of the topical therapies Protopic and Advantan as well as their combination against placebo in a Psoriasis Plaque Test |
| NCT00275535 ↗ | The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients | Completed | Genzyme, a Sanofi Company | Phase 4 | 2001-04-01 | This study was done to find out which treatment, tacrolimus or sirolimus, leads to better long-term kidney function in kidney transplant patients. |
| NCT00275535 ↗ | The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients | Completed | Roche Pharma AG | Phase 4 | 2001-04-01 | This study was done to find out which treatment, tacrolimus or sirolimus, leads to better long-term kidney function in kidney transplant patients. |
| NCT00275535 ↗ | The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2001-04-01 | This study was done to find out which treatment, tacrolimus or sirolimus, leads to better long-term kidney function in kidney transplant patients. |
| NCT00275535 ↗ | The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients | Completed | Mayo Clinic | Phase 4 | 2001-04-01 | This study was done to find out which treatment, tacrolimus or sirolimus, leads to better long-term kidney function in kidney transplant patients. |
| NCT00358657 ↗ | Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Nonca | Terminated | National Cancer Institute (NCI) | Phase 2 | 2006-05-24 | This phase I/II trial studies the side effects of fludarabine phosphate, cyclophosphamide and total-body irradiation followed by donor bone marrow transplant and cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus in treating patients with primary immunodeficiency disorders or noncancerous inherited disorders. Giving low doses of chemotherapy and total-body irradiation before a bone marrow transplant helps prepare the patient's body to accept the incoming donor's bone marrow and decrease the risk that the patient's immune system will reject the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells called graft versus host disease. Giving cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus after the transplant may help decrease this from happening. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PROTOPIC
Condition Name
Clinical Trial Locations for PROTOPIC
Trials by Country
Clinical Trial Progress for PROTOPIC
Clinical Trial Phase
Clinical Trial Sponsors for PROTOPIC
Sponsor Name
